Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0175717 http://scihub22266oqcxt.onion/10.1371/journal.pone.0175717 C5395178!5395178 !28419124     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28419124 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       PLoS+One 2017 ; 12 (4 ): e0175717 Nephropedia Template TP {{tp|p=28419124 |t=2017. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis |pdf=|usr=}}{{28419124 }} gab.com Text A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=28419124 #FOAvip INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH). METHODS: Double-blind randomised-controlled trial of Losartan 50 mg once a day versus placebo for 96 weeks in patients with histological evidence of NASH. The primary outcome for the study was change in histological fibrosis stage from pre-treatment to end-of-treatment. RESULTS: The study planned to recruit 214 patients. However, recruitment was slower than expected, and after 45 patients were randomised (median age 55; 56% male; 60% diabetic; median fibrosis stage 2), enrolment was suspended. Thirty-two patients (15 losartan and 17 placebo) completed follow up period: one patient (6.7%) treated with losartan and 4 patients (23.5%) in the placebo group were "responders" (lower fibrosis stage at follow up compared with baseline). The major reason for slow recruitment was that 39% of potentially eligible patients were already taking an ARB or angiotensin converting enzyme inhibitor (ACEI), and 15% were taking other prohibited medications. CONCLUSIONS: Due to the widespread use of ACEI and ARB in patients with NASH this trial failed to recruit sufficient patients to determine whether losartan has anti-fibrotic effects in the liver. TRIAL REGISTRATION: ISRCTN 57849521. Twit Text FOAVip A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=28419124 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28419124 #FOAvip English Wikipedia <ref>{{Cite pmid|28419124 }}</ref> A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis #MMPMID28419124 McPherson S ; Wilkinson N ; Tiniakos D ; Wilkinson J ; Burt AD ; McColl E ; Stocken DD ; Steen N ; Barnes J ; Goudie N ; Stewart S ; Bury Y ; Mann D ; Anstee QM ; Day CP PLoS One 2017[]; 12 (4 ): e0175717 PMID28419124 show ga INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH). METHODS: Double-blind randomised-controlled trial of Losartan 50 mg once a day versus placebo for 96 weeks in patients with histological evidence of NASH. The primary outcome for the study was change in histological fibrosis stage from pre-treatment to end-of-treatment. RESULTS: The study planned to recruit 214 patients. However, recruitment was slower than expected, and after 45 patients were randomised (median age 55; 56% male; 60% diabetic; median fibrosis stage 2), enrolment was suspended. Thirty-two patients (15 losartan and 17 placebo) completed follow up period: one patient (6.7%) treated with losartan and 4 patients (23.5%) in the placebo group were "responders" (lower fibrosis stage at follow up compared with baseline). The major reason for slow recruitment was that 39% of potentially eligible patients were already taking an ARB or angiotensin converting enzyme inhibitor (ACEI), and 15% were taking other prohibited medications. CONCLUSIONS: Due to the widespread use of ACEI and ARB in patients with NASH this trial failed to recruit sufficient patients to determine whether losartan has anti-fibrotic effects in the liver. TRIAL REGISTRATION: ISRCTN 57849521. |Adult [MESH] |Aged [MESH] |Angiotensin II Type 1 Receptor Blockers/therapeutic use [MESH] |Double-Blind Method [MESH] |Drug Administration Schedule [MESH] |Female [MESH] |Fibrosis/prevention & control [MESH] |Humans [MESH] |Liver Cirrhosis/*prevention & control [MESH] |Liver/*drug effects/pathology [MESH] |Losartan/*therapeutic use [MESH] |Male [MESH] |Middle Aged [MESH] |Non-alcoholic Fatty Liver Disease/*drug therapy [MESH] |Treatment Outcome [MESH]A randomised controlled trial of losartan as an anti-fibrotic agent in(epmc).pdf DeepDyve Pubget Overpricing